Efficiency perindopril at patients with arterial hypertension and obesity

Kardiologiya

Volumn 51, Issue 11, 2011, Pages 38-44

  Nedogoda, S V ^a   Ledyaeva, A A ^a   Chumachok, E V ^a   Csoma, V V ^a   Mazina, G G ^a   Salasyuk, A S ^a   Barykina, I N ^a  

^a VOLGOGRAD STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Arterial hypertension; Obesity; Perindopril

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PERINDOPRIL; PROTECTIVE AGENT;

ADIPOSE TISSUE; ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; COMPARATIVE STUDY; DRUG EFFECT; DRUG MONITORING; FEMALE; HEART FUNCTION TEST; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FUNCTION TEST; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; OBESITY; PATHOPHYSIOLOGY; PHARMACOKINETICS; TREATMENT OUTCOME;

ADIPOSE TISSUE; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; BODY MASS INDEX; DRUG MONITORING; ENALAPRIL; FEMALE; HEART FUNCTION TESTS; HUMANS; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FUNCTION TESTS; MALE; METABOLIC PHENOMENA; MIDDLE AGED; OBESITY; PERINDOPRIL; PROTECTIVE AGENTS; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 84857186475     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Naik S. Nakamura T., Kawachi K. et al. Effects of ARB or ACE-Inhibitor Administration on Plasma Levels of Aldosterone and Adiponectin in Hypertension. Intern Heart J 2009;50:501-512.
2. Sharma A. M., Pischon T., Engeli S. et al. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001;19:667-674.
3. Ghiadoni L., Magagna A., Versari D. et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003;41:1281-1286.
4. Guo W, Turlapaty P., Shen Y. et al. Clinical experience with perindopril in patients nonresponsive to previous antihypertensive therapy: a large US community trial. Am J Ther 2004;11:199-205.
5. Ludwig D. S. Childhood Obesity - The Shape of Things to Come. N Engl J Med 2007;357:2325.
6. Poggi L., Renucci J. F., Denolle T. Treatment of essential hypertension in general practice: an open-label study of 47, 351 French hypertensive patients treated for one year with perindopril. Can J Cardiol 1994;10(Suppl. D):21D-24D.
7. Yasuda G., Hasegawa K. et al. Perindopril effects on ambulatory blood pressure: relation to sympathetic nervous activity. Am J Hypertens 2004;17:14-20.
8. Jandrain B. et al. Long-term acceptability of perindoprol in type 11 diabetic patients with hypertension. Am J Med 1992;92:91-94.
9. Andrejak M. et al. A double-blind comparison of perindopril and HCTZ-amiloride in mild to moderate essential hypertension. Fundam Clin Pharmacol 1991;5:185-192.
10. Tykarski A. et al. Comparation of the effects of the angiotensin 11 antagonists and ACE inhibitors on renal handling of uric acid in hypertensive patients. Nephrol Dial Transplant 1999;14:A62.
11. Böhlen L., Bienz R., Doser M. et al. Metabolic neutrality of perindopril: focus on insulin sensitivity in overweight patients with essential hypertension. J Cardiovasc Pharmacol 1996;27:770-776.
12. Fogari R. et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002;15:316-320.
13. Mathai M., Naik S. et al. Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats. Intern J Obes 2008;32:1576-1584.
14. Brasier A., Recinos A., Eledrisi M. Vascular Inflammation as a Cardiovascular Risk Factor Principles of Molecular Cardiology. Contemporary Cardiology 2005;6:577-604.
15. Gabbani S. et al. Effects of perindopril on carbohydrate and lipoprotein metabolism in essential hypertension. Am J Med 1992;4:95-97.
16. Yuan L. I., Wang Xiao-ming et al. Effects of perindopril on sICAM-1 and Fas/Apo-1 in peripheral blood of elderly patients with congestive heart failure. Chinese J Geriatr Cardiovasc Cerebrovasc Dis 2004;02:112-116.
17. Madej A., Buldak L. et al. The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines. Int J Clin Pharmacol Ther 2009;47:686-694.
18. Wang X. M., Li Y., Li H. F. et al. Effects of perindopril on soluble intercellular adhesion molecule-1 in patients with congestive heart failure. Heart 2002;88:417.
19. Ying Li., Song Yaoming et al. Effects of perindopril and candesartan on left ventricular remodeling and serum ET-1. IL-6 and MMP-9 levels in patients with chronic heart failure. Acta Academiae Medicinae Militaris Tertiae 2011;06:127-131.
20. Ficek J., Kokot F., Chudek J. et al. Influence of antihypertensive treatment with perindopril, pindolol or felodipinon plasma leptin concentration in patients with essential hypertension. Horm Metab Res 2002;34:703-708.
21. Krysiak I R., Sierant M. et al. The effect of angiotensin-converting enzyme inhibitors on plasma adipokine levels in normotensive patients with coronary artery disease. Pol J Endocrinol 2010;61:280-286.
22. Krysiak I R., Sierant I M. et al. The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease. Pol J Endocrinol 2010;61:683-690.
23. Lubel J. Liver Disease and the Renin-angiotensin System: Recent Discoveries and Clinical Implications. Gastroenterol Hepatol 2008;23:1327-1338.
24. Yoshiji H., Kuriyama S., Yoshii J. et al. Angiotensin-ll type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001;34:745-750.
25. Yoshiji H., Kuriyama S., Kawata M. et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 2001;7:1073-1078.